BioCentury | Sep 16, 2020

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

The picture Nisa Leung, managing director of Qiming Venture Partners, paints of the response among Chinese biotechs to COVID-19 is one that underscores how the local ecosystem has matured from a “budding...
BioCentury | Jun 9, 2020

AstraZeneca eyes August trial start for COVID-19 mAb pair

AstraZeneca is joining the COVID-19 neutralizing antibody race with a pair of candidates licensed from Vanderbilt to treat or prevent the infection that are slated to begin clinical testing in August. The company also announced...
BioCentury | Jun 2, 2020
Product Development

Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...
BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 3, 2020
Product Development

COVID-19 roundup: Amgen taps Adaptive as its antibody therapeutic partner; plus Alnylam-Vir’s siRNA targets, Ansun’s data and more

Amgen entered the race to develop an antibody-based COVID-19 therapy Thursday, partnering with Adaptive Biotechnologies to screen for neutralizing mAbs. The day also saw Alnylam and Vir name the first targets from their siRNA partnership...
BioCentury | Apr 1, 2020
Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

Backed by preclinical and clinical data that support blocking complement to mitigate coronavirus-mediated respiratory distress, InflaRx has begun a clinical study of its own complement inhibitor to treat COVID-19 patients with severe pneumonia. InflaRx N.V....
BioCentury | Mar 28, 2020
Product Development

COVID-19 diagnostic tech tableau

In the ramp-up of testing for COVID-19, two well-established technologies have divided the forefront: RT-PCR and immunoassays. The former tests for active infection by detecting viral RNA, while the latter can be used to detect...
BioCentury | Mar 26, 2020

March 25 Quick Takes: Temasek leads Abbisko’s $70M C round; plus IASO and Regenacy

Abbisko raises $70M series C Abbisko Therapeutics Co. Ltd. raised $70 million in a series C round, bringing the total funds raised by the cancer company to $140 million since its founding in 2016. Temasek...
Items per page:
1 - 10 of 809